Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:FDMT NASDAQ:KRRO NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.64-1.4%$3.83$2.90▼$11.16$325.67M0.182.49 million shs1.76 million shsFDMT4D Molecular Therapeutics$6.81-3.7%$5.70$2.23▼$17.41$318.04M2.86617,578 shs517,375 shsKRROKorro Bio$30.76-10.6%$19.29$10.29▼$98.00$322.95M2.66229,665 shs237,420 shsWHWKWhitehawk Therapeutics$1.99-1.0%$1.81$1.39▼$3.81$94.73M0.51115,090 shs242,266 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-1.36%-3.70%-2.67%-47.40%-49.23%FDMT4D Molecular Therapeutics-3.68%-6.33%+2.10%+55.13%-56.68%KRROKorro Bio-10.56%-7.29%+62.49%+127.18%-25.83%WHWKWhitehawk Therapeutics-1.00%+9.34%+16.37%+198,999,900.00%+198,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.64-1.4%$3.83$2.90▼$11.16$325.67M0.182.49 million shs1.76 million shsFDMT4D Molecular Therapeutics$6.81-3.7%$5.70$2.23▼$17.41$318.04M2.86617,578 shs517,375 shsKRROKorro Bio$30.76-10.6%$19.29$10.29▼$98.00$322.95M2.66229,665 shs237,420 shsWHWKWhitehawk Therapeutics$1.99-1.0%$1.81$1.39▼$3.81$94.73M0.51115,090 shs242,266 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-1.36%-3.70%-2.67%-47.40%-49.23%FDMT4D Molecular Therapeutics-3.68%-6.33%+2.10%+55.13%-56.68%KRROKorro Bio-10.56%-7.29%+62.49%+127.18%-25.83%WHWKWhitehawk Therapeutics-1.00%+9.34%+16.37%+198,999,900.00%+198,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.57Moderate Buy$17.40378.02% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40346.40% UpsideKRROKorro Bio 3.29Buy$86.83182.29% UpsideWHWKWhitehawk Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest WHWK, KRRO, ALT, and FDMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.008/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/13/2025KRROKorro BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$153.00 ➝ $147.008/13/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $90.008/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/11/2025WHWKWhitehawk TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,062.77N/AN/A$1.74 per share2.09FDMT4D Molecular Therapeutics$33K9,637.59N/AN/A$11.05 per share0.62KRROKorro Bio$6.28M45.99N/AN/A$17.12 per share1.80WHWKWhitehawk Therapeutics$25.98M3.61N/AN/A$2.12 per share0.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)KRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)WHWKWhitehawk Therapeutics-$63.69M-$0.06N/A∞N/A99.42%-75.99%-68.57%N/ALatest WHWK, KRRO, ALT, and FDMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 million8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/7/2025Q2 2025WHWKWhitehawk Therapeutics$0.49-$0.76-$1.25-$0.76$100.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44FDMT4D Molecular TherapeuticsN/A8.758.75KRROKorro BioN/A5.985.98WHWKWhitehawk TherapeuticsN/A20.4120.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%FDMT4D Molecular Therapeutics99.27%KRROKorro Bio13.18%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%FDMT4D Molecular Therapeutics9.60%KRROKorro Bio4.60%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableKRROKorro Bio709.39 million8.96 millionNo DataWHWKWhitehawk Therapeutics2147.13 million23.61 millionN/AWHWK, KRRO, ALT, and FDMT HeadlinesRecent News About These CompaniesWhitehawk Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2025 | prnewswire.comWhitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsAugust 7, 2025 | prnewswire.comWhitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s EndBy Thomas Hughes | August 19, 2025WHWK, KRRO, ALT, and FDMT Company DescriptionsAltimmune NASDAQ:ALT$3.64 -0.05 (-1.36%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.67 +0.03 (+0.71%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.4D Molecular Therapeutics NASDAQ:FDMT$6.81 -0.26 (-3.68%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.81 0.00 (0.00%) As of 09/12/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Korro Bio NASDAQ:KRRO$30.76 -3.63 (-10.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$30.82 +0.06 (+0.20%) As of 09/12/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Whitehawk Therapeutics NASDAQ:WHWK$1.99 -0.02 (-1.00%) As of 09/12/2025 04:00 PM EasternAadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
